Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Harrow Inc
(NQ:
HROW
)
44.22
+1.52 (+3.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harrow Inc
< Previous
1
2
3
4
Next >
Harrow Announces Second Quarter 2024 Financial Results
August 07, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
July 25, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow to Attend 2024 ASRS Annual Meeting
July 12, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
July 09, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Provides TRIESENCE® Relaunch Update
June 20, 2024
From
Harrow, Inc.
Via
Business Wire
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
June 06, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
June 05, 2024
From
Harrow, Inc.
Via
Business Wire
3 Stocks Insiders are Buying That Should be on Your Radar
May 28, 2024
Unusual insider activity indicates opportunities in these stocks positioned to deliver value for shareholders this year.
Via
MarketBeat
Harrow to Present at Two Investor Conferences in May
May 15, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Announces First Quarter 2024 Financial Results
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
April 25, 2024
From
Harrow, Inc.
Via
Business Wire
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
April 02, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
March 19, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
March 05, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
February 15, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Announces New Appointments to its Board of Directors
January 29, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
January 11, 2024
From
Harrow, Inc.
Via
Business Wire
Melt Pharmaceuticals Provides Corporate Update
January 03, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 03, 2024
From
Harrow, Inc.
Via
Business Wire
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 29, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow to Present at Two Investor Conferences in November
November 20, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Announces Third Quarter 2023 Financial Results
November 13, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
October 30, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
October 24, 2023
From
Harrow, Inc.
Via
Business Wire
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
September 29, 2023
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
September 26, 2023
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Announces Second Quarter 2023 Financial Results
August 09, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow Launches VIGAMOX® in the U.S.
July 31, 2023
From
Harrow Health, Inc.
Via
Business Wire
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
July 26, 2023
From
Harrow Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.